Boule Diagnostics AB (publ) (STO: BOUL)

Market Cap	264.84M
Revenue (ttm)	563.33M
Net Income (ttm)	-212.52M
Shares Out	38.83M
EPS (ttm)	-5.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,131
Open	7.02
Previous Close	6.74
Day's Range	6.68 - 7.02
52-Week Range	6.68 - 12.62
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Boule Diagnostics AB

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1956
• Employees: 228
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BOUL

Financial Performance

In 2023, Boule Diagnostics AB's revenue was 571.33 million, an increase of 4.24% compared to the previous year's 548.09 million. Earnings were 24.98 million, an increase of 96.24%.